Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Clinical Development Programme

BAY 2731954 (LOXO-195) is being studied in a single phase 1/2 clinical trial [1, 2]. This is a real-time, safety- and pharmacokinetic-guided study in patients with advanced cancers with NTRK gene fusion whose tumours have progressed on a prior TRK inhibitor [3].  As of December 2019, 31 cancer patients with NTRK gene fusion (7 paediatric, 24 adults) with 11 cancer types had been treated [4]. In the phase 1 part of the study in which doses of 32 mg once-a-day to 150 mg twice-a-day were evaluated, adverse events included dizziness/ataxia (65% of patients), nausea/vomiting (50%) of patients, anaemia (30%), myalgia, abdominal pain, fatigue and lymphopenia (all in 20% of patients each). Overall responses occurred in 10/29 patients (34%). Dose selection is ongoing. 

Table 14: Summary of Ongoing Clinical Trials for BAY 2731954 (LOXO-195)

Registry number

Phase

Title

NCT03215511
EudraCT 2017-004246-20

1/2

Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

These data are current as of 6 June 2019 ( clinicaltrials.gov)

References

  1. Lassen UN, Albert CM, Kummar S et al. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. Annals of Oncology 2018; 29: mdy279.397-mdy279.397, https://doi.org/210.1093/annonc/mdy1279.1397.
  2. Sartore-Bianchi A, Ardini E, Bosotti R et al. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl Cancer Inst 2016; 108.
  3. Drilon A, Nagasubramanian R, Blake JF et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov 2017; 7: 963-972.
  4. Hyman D, Kummar S, Farago A et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Presented at: AACR Annual Meeting: March 29 to April 3, 2019; Atlanta, GA. Abstract CT127. 2019.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings